Lakefront Biotherapeutics (GLPGF) Tax Provisions (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Tax Provisions for 13 consecutive years, with -$151107.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions fell 17.1% year-over-year to -$151107.0 in Q2 2026; TTM through Jun 2026 was $21.7 billion, a 592429.73% increase from a year earlier, with the FY2025 full-year figure at $21.0 billion, up 1077977.81% from the prior year.
• Tax Provisions was -$151107.0 for Q2 2026 at Lakefront Biotherapeutics, down from -$81952.2 in the prior quarter.
• Over five years, Tax Provisions peaked at $21.7 billion in Q4 2025 and troughed at -$580.3 million in Q4 2022.
• A 5-year average of $1.2 billion and a median of -$117951.5 in 2024 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions sank 29932.97% in 2022 and soared 20263338.43% in 2025, its largest moves.
• Over 5 years, Tax Provisions stood at -$580.3 million in 2022, then jumped by 99.61% to -$2.3 million in 2023, then soared by 95.27% to -$106859.5 in 2024, then soared by 20263338.43% to $21.7 billion in 2025, then plunged by 100.0% to -$151107.0 in 2026.
• The last three Tax Provisions figures came in at -$151107.0 (Q2 2026), -$81952.2 (Q1 2026), and $21.7 billion (Q4 2025), per Business Quant data.